
Krishna Institute of Medical Sciences Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Expansion plans include adding 350-400 beds via new towers and new hospitals in Thane, Nashik, Bengaluru, and Vizag.
- Vizag hospital acquisition currently generates around INR 65-70 crores revenue, with potential to scale back to INR 120-150 crores.
- IP volumes show consistent growth (7.5% YoY), with ongoing efforts to optimize Operational Metrics like Average Length of Stay (ALOS).
- Existing hospitals expected to sustain growth, with incremental contributions from newly acquired or commissioned hospitals like Queen’s NRI and Nashik.
- Occupancy targets of 65-70% over next 3-4 years expected to drive volume growth.
- Insurance penetration growth is significant in metro and Tier 1 cities but slower in Tier 2 and 3.
- EBITDA margin growth expected with revenue scale-up and new specialties added.
- Capital constraints may limit bed capacity expansion unless leverage or funding (IPO/debt) raised.
See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- KIMS Hospitals plans to fund growth primarily through internal accruals and debt while maintaining a debt-equity ratio within 0.75:1 and debt-to-EBITDA below 1.75:1.
- The company may slightly exceed their capex and EBITDA limits in the next 2-3 quarters but plans to stabilize thereafter.
- For expansion opportunities, they consider two options: raising funds via an IPO or taking on some debt leverage.
- Current average cost of borrowing is about 8.5%, and they expect this to continue in the near term.
- No immediate plans for a large-scale equity raise; focus is on using internal resources complemented by manageable debt to fund ongoing and future expansions.
- Debt is expected to increase from around INR1,150 crores as of June 2024 to INR1,600-1,700 crores by year-end due to new hospital commissions.
See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.
Capex plans
Yes- Construction of a new tower replacing demolished Block 1 and Block 2 at Secunderabad, accommodating 350-400 incremental beds; capex incurred over time as required (Page 18).
- Vizag unit acquisition with potential for scale-up; capital costs to be managed via internal accruals and controlled debt (Page 20, 7).
- Capex planned for upgrading acquired cancer facility (~INR 20-25 crores for renovations) without major medical equipment spend for 2-3 years (Page 8).
- New hospital cluster development in Karnataka (Sarjapura land parcel) planned post stabilization of currently acquired hospitals; equity infusion from partners (Page 12).
- Upcoming hospital launches in Nashik, Thane, and Bengaluru on track; Nashik operationalizing 75-80 beds, capex partially incurred or ongoing (Page 6, 7, 16).
- Capex and EBITDA cautiously managed; possibility to cross existing limits temporarily in 2-3 quarters to seize growth opportunities, with options for IPO or limited debt leverage if needed (Page 20).
- Capital constraint is a primary limit; company aims to keep debt-equity at 0.75:1 and debt-to-EBITDA at 1.75:1 (Page 16).
Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed
How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?
Pro featureHow does Krishna Institute of Medical Sciences rank in Healthcare Services?
Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Krishna Institute of Medical Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.